You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a novel mobile application to assist in the diagnosis of Fetal Alcohol Syndrome (FAS)

    SBC: Blue Resonance, LLC            Topic: 270

    Project Summary AbstractFetal alcohol spectrum disorderFASDis a major public health issue resulting from prenatal alcohol exposurePAEimpacting betweenof the US population and perhaps more thanchildren globally each yearWhen assessing for FASD the following facial features must to be evaluated as part of the diagnostic processpalpebral fissure lengthPFLthinness of the upper vermillionand the smooth ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Additive Manufactured PEKK Implants for Small Bone Arthroplasty

    SBC: Oxford Performance Materials, Inc.            Topic: NIAMS

    ABSTRACT This Phase I STTR is designed to evaluate the feasibility of using the OsteoFabtechnology platform for joint arthroplastyArthroFabdevicesspecifically targeting replacement of the small carpal bones in the wrist and hemiarthroplastyOsteoFabtechnology is the combination of Oxford Performance Materialsandaposproprietary formulation of polyetherketoneketoneOXPEKKpolymerand additive manufactur ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.

    SBC: Douleur Therapeutics Inc            Topic: NINDS

    Project Summary AbstractUpwards ofmillion individuals are afflicted by chronic pain in the US alonewithmillion of these individuals suffering from neuropathic painOn a global scalechronic pain affectsbillion individualswithwho endure lower back painFrom a clinical perspectivethe International Association for the Study of Pain approximates thatinpatients present with painand on an annual basisinpat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Southeast Xlerator Network

    SBC: XLERATEHEALTH, LLC            Topic: R

    The Southeast XLerator Network proposes to create a networked and easily accessible regional technology transfer accelerator hub (“XLerator Hub” or “Hub”) to share best practices, disseminate education content, and offer products, services, facilities and other resources connected through both physical and online platforms for innovators and trainees in the Southeast IDeA states. Led by XL ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. High-Throughput Assay for Profiling Alternative Splicing and Splicing Regulators

    SBC: Biospyder Technologies, Inc.            Topic: 172

    SummaryThis Phase I program will develop TempO Splicea highly multiplexed targeted sequencing assay monitoring RNA Binding ProteinRBPsplicing expression and alternatively splicedASmRNA representatives of coregulated splicing modulesa novel variation of the TempO Seqassay used for high throughput screeningdesigned to address the hypothesis that it is possible to provide a surrogate assay of the who ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Oncolytic virus-mediated target delivery of a therapeutic antibody fragment in glioblastoma

    SBC: Oncosynergy, Inc.            Topic: 102

    PROJECT SUMMARY More thanpatients are diagnosed each year with glioblastomathe most common primary brain tumorCurrent treatments are inadequate and there have been no major therapeutic breakthroughs in decadesHencethere is an urgent need to develop novel strategies to address this devastating diseaseHoweverdevelopment of an effective treatment for glioblastoma is severely hampered bythe blood brai ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Fully Human Antibodies for the Prevention of Respiratory Syncytial Virus

    SBC: IDBIOLOGICS INC            Topic: NIAID

    The goal of this STTR is to provide a preclinically validated monoclonal antibody or antibody combination for the prevention of respiratory syncytial virusRSVin high risk patients including infants and the elderlyWorldwideof children are infected with RSV before the age ofresulting in an estimatedmillion lower respiratory tract infectionsIn the United States adults overhavemillion RSV infections c ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Optical photothermal IR (O-PTIR) microscopy for chemical imaging of living cells at sub-micron resolution

    SBC: PHOTOTHERMAL SPECTROSCOPY CORP.            Topic: 102

    Optical photothermal IR (OPTIR) microscopy for chemical imaging of living cells at sub-micron resolution Project Summary/Abstract Photothermal Spectroscopy Corp (PSC) and Prof. Ji-Xin Cheng of Boston University in collaboration with Prof. Rohith Reddy (University of Houston) propose to develop, validate, and commercialize a novel technical called Optical Photothermal Infrared (OPTIR) spectroscopy. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    Seventeen million people each year suffer from an ischemic stroke and millions are left dead and disabledTreatment with recombinant tissue plasminogen activatorr tPAis only modestly effective at reducing disability and it is associated with brain hemorrhage in up toof patients when serial imaging studies are performedBrain hemorrhage causes death and disability andis the major cause of early morta ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer Metastases

    SBC: Nami Therapeutics Corp.            Topic: 102

    PROJECT SUMMARY ABSTRACT Ovarian cancer is the second most common gynecologic cancer in the United States and the most common cause of death among women with gynecologic malignanciesDespite advances in treatment strategiesperitoneal metastasis remains the primary cause of morbidity and mortality in ovarian cancerThe National Cancer Research Institute Clinical and Translational Radiotherapy Researc ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government